FDA Approves 7.2 mg Wegovy HD Shot for Greater Weight Loss
The U.S. Food and Drug Administration has approved Wegovy HD, a new 7.2 mg injection of semaglutide from Novo Nordisk that triples the previous maximum 2.4 mg dose and is indicated for chronic weight management in adults with obesity or overweight plus at least one weight‑related condition. The decision, announced Thursday, is the fourth approval under the FDA’s National Priority Voucher pilot, which Commissioner Dr. Martin Makary says is meant to fast‑track products that address critical national health priorities such as obesity. Clinical data from the STEP UP trial showed patients on the higher dose lost an average of 20.7% of their body weight versus about 16% on the standard dose, with roughly one‑third losing 25% or more, while blood‑sugar reductions in people with type 2 diabetes were similar to the lower dose. The agency says the safety profile mirrors known GLP‑1 side effects like nausea, vomiting and abdominal pain but notes more frequent skin sensitivity and burning at higher doses, which it is investigating, and it warns the drug should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Obesity and diabetes specialists say the new dose creates an evidence‑based escalation path for patients who plateau on 2.4 mg, though they caution it should be reserved for serious obesity management rather than cosmetic weight loss.
📌 Key Facts
- FDA approved Wegovy HD, a 7.2 mg semaglutide injection for adult weight loss and long‑term weight maintenance, on Thursday.
- The 7.2 mg dose is triple the prior maximum Wegovy dose of 2.4 mg and is the fourth product cleared under the FDA’s National Priority Voucher pilot program.
- In the STEP UP trial, patients on 7.2 mg lost an average 20.7% of body weight compared with about 16% on 2.4 mg; about one‑third lost at least 25% of their body weight.
- The FDA says higher doses caused more skin sensitivity, pain or burning at injection sites, now under investigation, and reiterates contraindications for patients with certain thyroid cancers or multiple endocrine neoplasia syndrome type 2.
📊 Relevant Data
In 2017-2018, the prevalence of adult obesity was 49.6% among non-Hispanic Black adults, 44.8% among Hispanic adults, 42.2% among non-Hispanic White adults, and 17.4% among non-Hispanic Asian adults in the United States.
Overweight & Obesity Statistics — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
In 2017-2020, the prevalence of diabetes was 14.6% among Black participants, 13.5% among Hispanic participants, and 10.6% among White participants in the United States.
Prevalence of diabetes in the USA from the perspective of demographic indices — Frontiers in Endocrinology
Black people are about four times less likely to receive a prescription for semaglutide (GLP-1 drugs like Ozempic and Wegovy) compared to White people in the United States.
Why Are Drugs Like Ozempic More Difficult to Access for Black People? — Healthline
Among people prescribed GLP-1 drugs like Ozempic, Mounjaro, Wegovy, and Rybelsus in 2021-2022, 65% were non-Hispanic White (compared to 59% of the U.S. population), while 14% were Hispanic or Latino (compared to 19% of the population).
Why Are Drugs Like Ozempic More Difficult to Access for Black People? — Healthline
Narrow-sense heritability estimates for type 2 diabetes in African Americans range from 18% to 34%, which are lower than prior estimates of 25-80% primarily from European or Asian populations.
Variant level heritability estimates of type 2 diabetes in African American: The PAGE Study — Scientific Reports (Nature)
📰 Source Timeline (1)
Follow how coverage of this story developed over time